Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress

Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company leveraging its proprietary BHT-DNA™ platform to develop targeted autoimmune disease treatments, today announced that it will present at the 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis and 15^th Annual Conference of Rehabilitation in MS in Gothenburg, Sweden, data from its concluded Phase 2 clinical trial showing that baseline blood plasma anti-MBP (myelin basic protein) profiles identify responders to BHT-3009 treatment. The abstract to be presented entitled "Baseline plasma anti-MBP antibody levels correlate with subject response to BHT-3009, a novel, antigen-specific tolerising DNA vaccine therapy for MS patients," is being shown as poster #417 in poster session 1.

“Baseline plasma anti-MBP antibody levels correlate with subject response to BHT-3009, a novel, antigen-specific tolerising DNA vaccine therapy for MS patients”

Data in the abstract indicate that BHT-3009 has the potential to be the first personalized medicine for MS patients, by selecting for patients with high anti-MBP antibodies in their blood. The best responders had an 86% reduction in brain MRI (magnetic resonance imaging) gadolinium-enhancing lesion and 77% reduction in new and enhancing T2 lesions compared to placebo. This group also had a 67% reduction in the annualized relapse rate compared to placebo.

Hideki Garren, MD, PhD, COO, CSO, EVP and Co-founder of Bayhill Therapeutics, commented, "We are pleased to report the identification of a simple blood-based biomarker that predicts responders to BHT-3009. The results reported here combined with the excellent safety and tolerability of BHT-3009 shown to date support further clinical testing, and make BHT-3009 potentially the first personalized treatment available for MS patients."